 BioMarin Pharmaceutical Inc., a drug maker focused on rare diseases, said it has agreed to pay up to $840 million to acquire Prosensa Holding NV, a Dutch biopharmaceutical company with no marketed products.. The deal is a bet that regulators will approve Prosensa’s lead product candidate for a rare form of muscular dystrophy, despite the drug’s...
  